Synopsis: A speciality chemicals and amines manufacturer more than doubled its profit in the June quarter, helped by better margins even as volumes stayed muted. Alongside the results, the company commissioned a first-of-its-kind plant in India and continues executing a large multi-year expansion into new chemical categories.
A strong profit number usually tells only part of the story. This quarter, the more interesting part sits behind the headline print, in a plant that didn’t exist in India before this quarter, and in a larger expansion plan that’s steadily taking shape alongside it.
With a market capitalization of around ₹7,309 crore, shares of Balaji Amines Limited were trading near ₹2,285 apiece, within a 52-week range of ₹905 to ₹2,444, and a P/E of approximately 36x. The stock jumped 6 percent after the announcement
Profit More Than Doubled in Q1
Consolidated revenue for the quarter came in at ₹461 crore, up from ₹367 crore a year ago and ₹403 crore in the March quarter. EBITDA rose sharply to ₹121 crore, up 89% YoY from ₹64 crore, while the EBITDA margin expanded to 26% from 17% a year earlier. Net profit stood at ₹78 crore, up a striking 111% YoY from ₹37 crore, with the profit margin improving to 17% from 10%. Cash PAT, which adds back depreciation and deferred tax, came in at ₹97 crore against ₹51 crore a year ago. Diluted EPS for the quarter was ₹23.13, up from ₹19.99 in the previous quarter.
What stands out is that this margin and profit jump happened without much help from volumes. Total sales volume for the quarter was 21,587 MT, actually down from 27,570 MT a year earlier, meaning the improvement came almost entirely from better pricing and a richer product mix rather than selling more. The Amines & Speciality Chemicals segment remained the dominant driver, contributing the bulk of both revenue and profit, while the company’s hotel business added a smaller, steady slice.
India’s First Commercial DME Plant
The bigger news this quarter was the commissioning of a 100,000 TPA Dimethyl Ether, or DME, plant, which the company says is India’s first commercial-scale facility of its kind. DME is used in LPG blending and as an aerosol propellant, and this plant marks the company’s entry into alternate fuel applications, an area outside its traditional amines business.
The company isn’t stopping there. It has two more projects lined up for commissioning during FY27: an N-Methyl Morpholine unit and an expansion of its Acetonitrile capacity, both of which should widen its speciality chemicals portfolio further.
The Bigger ₹750 Crore Bet
Running alongside these projects is a larger, ₹750 crore phased expansion at the company’s subsidiary, which has been granted Mega Project Status by the Maharashtra government. This expansion is aimed at building an integrated platform for high-value chemicals like Hydrogen Cyanide, Sodium Cyanide, EDTA, and several downstream derivatives used in pharmaceuticals, agrochemicals, and mining.
A brownfield unit for EDA-based downstream products is expected to be commissioned this year, while a separate greenfield facility is under construction, with plants for hydrogen cyanide and related products also targeted for FY27. The idea behind this push is import substitution, many of these intermediates are currently brought in from abroad, and building domestic capacity could reduce that dependence while opening up a new, higher-margin revenue stream.
What Comes Next
Management has pointed to a healthy order pipeline and improving demand across the pharmaceutical, agrochemical, and alternate fuel markets the company serves, along with early positioning in the EV battery chemicals space. The company also remains a zero-debt business on a standalone basis, which gives it some room to keep funding these expansion plans without leaning heavily on borrowings.
The quarter’s numbers look strong, but the real test is whether the ongoing capacity additions, especially the DME plant and the larger cyanide chemistry platform, can convert into steady volume growth over the coming quarters, since this quarter’s profit surge came more from margins than tonnage. With multiple projects due to come online through FY27, the next few quarters should offer a clearer read on how much of this expansion translates into sustained earnings growth.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
